Routemaster Capital Enters Into Definitive Agreement to Acquire 49% Interest in DeFi Holdings Inc., a Company Pursuing Investments in the Decentralized Finance Market
November 18, 2020 08:30 ET
|
Routemaster Capital Inc.
TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Routemaster Capital Inc. (the “Company” or “Routemaster”) (TSXV: RM) is pleased to announce that it has entered into a definitive agreement dated as of...
Draganfly Announces Record Revenue and Gross Profit in Third Quarter 2020
November 17, 2020 09:15 ET
|
Draganfly Inc
Company Achieves Improved Quarterly Results Driven by Organic Growth, Recent Acquisition, and New COVID-19 Screening Products Los Angeles, CA, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Draganfly...
Routemaster Closes $2 Million Private Placement
November 16, 2020 08:00 ET
|
Routemaster Capital Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Routemaster Capital Inc. (TSXV: RM) (“Routemaster” or...
Hall of Famer and Former NBA and NCAA Champion Derek Anderson Joins Draganfly Board of Advisors
November 12, 2020 09:15 ET
|
Draganfly Inc
Anderson to help champion Draganfly’s Vital Intelligence technology into colleges and professional sports Los Angeles, CA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE:...
Draganfly Signs Definitive Option to Acquire 100% of the Assets of the subsidiaries of Global UAV Technologies: Pioneer Aerial Surveys Ltd and High Eye Aerial Imaging Inc.
November 10, 2020 09:15 ET
|
Draganfly Inc
Vancouver, BC, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer within the...
Basilea gibt Zulassung von Antibiotikum Zevtera® in China zur Behandlung von ambulant und im Spital erworbener Lungenentzündung bekannt
November 06, 2020 01:15 ET
|
Basilea Pharmaceutica AG
National Medical Products Administration (NMPA) erteilt Basileas Partner CR Gosun eine Drug Approval LicenseBasilea erhält CHF 3 Mio. Meilensteinzahlung von CR Gosun Basel, 06. November 2020 ...
Basilea announces approval of antibiotic Zevtera® in China to treat community-acquired pneumonia and hospital-acquired pneumonia
November 06, 2020 01:15 ET
|
Basilea Pharmaceutica AG
National Medical Products Administration (NMPA) granted Drug Approval License to Basilea’s partner CR GosunBasilea will receive CHF 3 million milestone payment from CR Gosun Basel, Switzerland,...
Draganfly to Provide Global Flight Services for Varigard™
October 29, 2020 09:15 ET
|
Draganfly Inc
Los Angeles, CA. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer within...
Draganfly to Host Shareholder Update Call Including Live Demo of its COVID-19 Focused Infectious Disease Screening Technology
October 28, 2020 09:15 ET
|
Draganfly Inc
Los Angeles, CA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer within the...
Basilea gibt Clinical Trial Collaboration and Supply Agreement mit Eli Lilly and Company für Ramucirumab für die laufende FIDES-03-Studie mit Derazantinib bei Magenkrebs bekannt
October 28, 2020 02:15 ET
|
Basilea Pharmaceutica AG
Basel, 28. Oktober 2020 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass sie ein Clinical Trial Collaboration and Supply Agreement mit Eli Lilly and Company für den Einsatz des...